TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3484773
Drug: Trimethoprim‐sulfamethoxazole (TMP‐SMZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim‐sulfamethoxazole (TMP‐SMZ), 320‐1,600 mg single‐dose
Study: 3484773
Drug: Trimethoprim‐sulfamethoxazole (TMP‐SMZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim‐sulfamethoxazole (TMP‐SMZ), 160‐800 mg twice a day for three days
Study: 26508702
Drug: 15LEU (70/15/180/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15LEU (70/15/180/30 g protein-leucine-carbohydrate-fat)
Study: 26508702
Drug: 5LEU (23/5/180/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5LEU (23/5/180/30 g protein-leucine-carbohydrate-fat)
Study: 16697496
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acid enriched parenteral nutrition
Study: 8746285
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g/day) for 28 days
Study: 1402620
Drug: Prednisolone, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone, 25 mg orally, three times daily for 8 days
Study: 3768084
Drug: Preparation A
Normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation A (Salbutax)
Study: 3768084
Drug: Preparation B
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation B (commercially available formulation)
Study: 31642985
Drug: Food-related behavioral
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food-related behavioral activation therapy (F-BA) for 12 months
Study: 21297126
Drug: Concurrent radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent radiation therapy (RT) with gefitinib and tipifarnib
Study: 27945892
Drug: Vaccine containing
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine containing Mycobacterium w, administered 0.1 ml intradermally on a weekly basis for 6 to 10 weeks.
Study: 27945892
Drug: Vaccine containing
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine containing Mycobacterium w
Study: 12017405
Drug: Clarithromycin ER
Normalized name: Clarithromycin ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin ER (two 500-mg tablets once daily for 7 days)
Study: 12017405
Drug: Trovafloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin (200 mg once daily for 7 days)
Study: 8018004
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of heparin nomogram
Study: 8018004
Drug: Heparin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin therapy with nomogram
Study: 8018004
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (rtPA, APSAC) with heparin
Study: 824553
Drug: Physiotherapeutic exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapeutic exercise therapy with bencyclane (treatment group, n = 45)
Study: 18474025
Drug: Intermittent high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent high dosage oral ibandronate
Study: 18474025
Drug: Daily low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily low dose ibandronate
Study: 15513977
Drug: Anastrozole ('Arimidex')
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole ('Arimidex') alone or in combination with tamoxifen
Study: 11996196
Drug: bisoprolol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg
Study: 10535718
Drug: amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine 5 mg
Study: 10215737
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of alendronate/day
Study: 7630617
Drug: Medication reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reduction
Study: 31317460
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration through a nasopharyngeal airway and standard nasal cannula
Study: 28067693
Drug: Intraoperative S-ketamine
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative S-ketamine bolus 0.5 mg/kg and infusion 0.25 mg·kg·h
Study: 24251378
Drug: Orlistat medication
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat medication therapy plus low-fat diet
Study: 18639327
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER (4 mg once daily)
Study: 11271790
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (500 mg daily) for 10 weeks
Study: 8199416
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) providing 41 +/- 2 kcal, 0.30 +/- 0.02 g N kg‐1.day‐1, and 40 mg pyridoxine for 14 days.
Study: 8199416
Drug: Taurine supplementation
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplementation at a dosage of 8.6 mg.kg‐1.day‐1.
Study: 27406028
Drug: FenuSMART™ (fenugreek
Approvals — FDA: no, EMA: no, PMDA: no
Description: FenuSMART™ (fenugreek extract) 1000 mg/day for 90 days
Study: 24356886
Drug: Hi-Xen infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hi-Xen infusion at 12 pmol · kg(‐1) · min(‐1)
Study: 24356886
Drug: Lo-Xen infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lo-Xen infusion at 4 pmol · kg(‐1) · min(‐1)
Study: 24356886
Drug: Hi-Xen infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hi-Xen infusion for 90 or 300 min
Study: 24356886
Drug: Hi-Xen infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hi-Xen infusion for 30 min
Study: 24356886
Drug: Hi-Xen infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hi-Xen infusion
Study: 18697894
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy intervention
Study: 15855325
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg/day) for 12 weeks
Study: 1833813
Drug: Clomipramine (CMP)
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomipramine (CMP) administered at progressive doses for 8 days (maximum dosage 75 mg) in the evening at 6 p.m.
Study: 1833813
Drug: Placebo (glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glucose solution infusion) administered morning and evening.
Study: 6801213
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (600 mg/day)
Study: 30711528
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone (200 mg bid)
Study: 22021897
Drug: Both DAS28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both DAS28 and MMP‐3‐driven therapy (T group)
Study: 22021897
Drug: MMP‐3‐driven therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMP‐3‐driven therapy (M group)
Study: 19346511
Drug: Metered-dose inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhaler (MDI) with 50 microg nicotine/puff
Study: 19346511
Drug: Metered-dose inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhaler (MDI) with 100 microg nicotine/puff
Study: 11229224
Drug: Aspirin (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (at lower doses)
Study: 7811344
Drug: S-adenosylmethionine (SAME);
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosylmethionine (SAME); 2 g daily in 250 ml 0.15 M NaCl for 15 days
Study: 7811344
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (alcoholic patients without treatment)
Study: 9511622
Drug: Myprodol (Ibuprofen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myprodol (Ibuprofen, Paracetamol and Codeine phosphate)
Study: 332607
Drug: Antacids containing
Normalized name: antacids containing calcium compounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids containing Mg (OH)2, Al (OH)3 and CaCO3, administered after meals
Study: 24377635
Drug: Had never
Normalized name: Haddock
DrugBank: Haddock (DB10615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Had never seen friends smoking in a school compound
Study: 19305020
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg and Simvastatin 40 mg (coadministered)
Study: 11704900
Drug: Behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural therapy (general)
Study: 9491231
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg once daily for 7 days)
Study: 7840417
Drug: Ketamine racemate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine racemate (1 mg/kg)
Study: 7840417
Drug: S(+)‐ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine (0.5 mg/kg)
Study: 28662281
Drug: Monthly provider
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly provider funnel plot feedback reports and semiannual face‐to‐face coaching sessions for 12 months
Study: 25970080
Drug: Autologous peripheral
Normalized name: Autologous peripheral blood-derived CD34+ cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous peripheral blood stem cell transplantation in addition to comprehensive medical treatment
Study: 25970080
Drug: Comprehensive medical
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive medical treatment alone (Control)
Study: 19551674
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03% once daily for 12 weeks
Study: 15214959
Drug: Ofloxacin plus
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin plus rifampicin (400 mg/day plus 600 mg/day for 30 days)
Study: 15214959
Drug: Doxycycline plus
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline plus rifampicin (200 mg/day plus 600 mg/day for 45 days)
Study: 10737828
Drug: Multiple-family group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-family group psychoeducation treatment
Study: 25758874
Drug: Gabapentin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (200 mg)
Study: 25758874
Drug: Levodopa-c (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa-c (110 mg)
Study: 23838349
Drug: Clofarabine 20
Normalized name: clofarabine 20 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofarabine 20 mg/m² on days 1 to 5 for up to 4 courses
Study: 23838349
Drug: Low-dose Ara-C
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Ara-C (LDAC) 20 mg twice daily for 10 days every 6 weeks for up to 4 courses
Study: 19427180
Drug: Routine medication
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medication (control group)
Study: 18782532
Drug: Jinlong Capsule
Normalized name: BUTYLENE GLYCOL 1.6 g in 8 g CUTANEOUS TAPE [LingLongJiuHuo Linglong Moxibustion]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinlong Capsule (TACE therapy plus Jinlong Capsule)
Study: 18782532
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (TACE therapy alone)
Study: 19476402
Drug: Risedronate 75
Normalized name: risedronate 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 75 mg taken on two consecutive days each month (2CDM)
Study: 19476402
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg taken once daily
Study: 19476402
Drug: Risedronate 75
Normalized name: risedronate 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 75 mg 2CDM and Risedronate 5 mg once daily
Study: 17969893
Drug: Zhiling Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhiling Capsule (ZLC)
Study: 17969893
Drug: Pingxiao Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pingxiao Capsule (PXC)
Study: 11806862
Drug: Nicotine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (2 mg administered by inhalator)
Study: 15232663
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg/day)
Study: 8874977
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg/day)
Study: 2328750
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg metamizol sodium
Study: 2328750
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg metamizol sodium
Study: 2328750
Drug: 3000 mg
Normalized name: talc 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 mg metamizol sodium
Study: 7307999
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (40 mg orally in delay‐action form and 5 mg sublingually)
Study: 6151343
Drug: Prazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (2 mg)
Study: 7307999
Drug: Dihydralazine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine (75 mg)
Study: 7307999
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (three times 20 mg)
Study: 7307999
Drug: Prazosin (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (three times 2 mg)
Study: 7307999
Drug: Dihydralazine (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine (three times 75 mg)
Study: 30994090
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (9.0 × 10^5 sporozoites, three doses)
Study: 30994090
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (9.0 × 10^5 sporozoites, one dose)
Study: 21070456
Drug: BoNTA injections
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BoNTA injections
Study: 8678514
Drug: 5-FU 10
Normalized name: 5-FU 10 MG/ML Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU 10 mg/kg/24 hrs c.i.v. x 24 days (arm A, n = 25)
Study: 8678514
Drug: 5-FU 20
Normalized name: 5-FU 20 MG/ML Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU 20 mg/kg/24 hrs c.i.v. x 4 days/w x 3 courses (arm B, n = 16)
Study: 8678514
Drug: 5-FU 30
Normalized name: Epinephrine 0.1 MG / 5-FU 30 MG Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU 30 mg/kg/24 hrs c.i.v. x 2 days/w x 4 courses (arm C, n = 25)
Study: 30666732
Drug: MgSO4 50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO4 50% solution (MSS at 40 mg/kg BW)
Study: 30666732
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose solution (DS; control solution at 2 mL/kg body weight)
Study: 24603102
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (50 mg daily)
Study: 19483659
Drug: MEDI-534 vaccine
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-534 vaccine (10 median tissue culture infectious dose50)
Study: 17634081
Drug: Patch test
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch test with a dilution series of 19 concentrations, duration up to 21 days
Study: 11286826
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (CT) with cisplatin 60 mg/m² and epirubicin 110 mg/m² followed by radiotherapy (RT)
Study: 11286826
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (CT) with cisplatin and epirubicin
Study: 8011248
Drug: Foscarnet at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet at a dose of 60 mg/kg every 8 h for 14 days followed by maintenance doses of 60 or 90 mg/kg/day.
Study: 8011248
Drug: Foscarnet at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet at a maintenance dose of 120 mg/kg/day.
Study: 8011248
Drug: Foscarnet therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet therapy compared to historic controls who terminated ganciclovir therapy.
Study: 3192364
Drug: Amoxicillin combined
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin combined with decongestive nose drops
Study: 3192364
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amoxicillin and drainage
Study: 21755342
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg aminophylline
Study: 21755342
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg aminophylline
Study: 21755342
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg aminophylline
Study: 21755342
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg aminophylline
Study: 21755342
Drug: aminophylline (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: aminophylline (2, 3, 4, 5 mg/kg)
Study: 21755342
Drug: aminophylline (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: aminophylline (4, 5 mg/kg)
Study: 18463672
Drug: Ramipril-HCT (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril-HCT (20 mg q.d.)
Study: 18463672
Drug: HCT monotherapy
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCT monotherapy
Study: 12594698
Drug: Acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine (600 mg twice a day 24 hr before and the day of cardiac catheterization)
Study: 12594698
Drug: Control (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (intravenous hydration alone)
Study: 9549283
Drug: Cilostazol (150-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (150-200 mg/day)
Study: 9549283
Drug: Warfarin (prothrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (prothrombin time controlled to 15-25%)
Study: 3708124
Drug: Buccal formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal formulations
Study: 3708124
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated ASA formulations
Study: 10442525
Drug: Fexofenadine 60
Normalized name: fexofenadine 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 60 mg
Study: 23033993
Drug: Concentrated fine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated fine particles from Chapel Hill air (PM(2.5)CAPs, 89.5 ± 10.7 µg/m³)
Study: 8569136
Drug: F‐CaP (supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: F‐CaP (supplemented formula with Ca 87 mg/dl, P 43 mg/dl)
Study: 8569136
Drug: F (non-supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: F (non-supplemented formula with Ca 62 mg/dl, P 36 mg/dl)
Study: 2121109
Drug: 0.2 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg/day recombinant human growth hormone (rHGH)
Study: 31238700
Drug: Clopidogrel and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel and aspirin for 90 days
Study: 21916906
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 2 g/day
Study: 8743000
Drug: Perifoveal laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perifoveal laser treatment
Study: 1350935
Drug: roxatidine 150
Normalized name: roxatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine 150 mg once daily
Study: 6424498
Drug: Alfentanil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (10 times the dose of fentanyl)
Study: 22728648
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate infusion (40 mg/kg for 15 min followed by 10 mg/kg/h during surgery)
Study: 20639739
Drug: Etodolac (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac (300 mg) - Paracetamol (500 mg) combination
Study: 20639739
Drug: Etodolac (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac (300 mg) alone
Study: 10856145
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 88 microg twice daily
Study: 1311658
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid solution starting on post-natal day 2 (Group A)
Study: 1311658
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group B) starting amino acid solution after day 4
Study: 3516000
Drug: Intramuscular meptazinol
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meptazinol (1 mg/kg)
Study: 3516000
Drug: Intramuscular pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pethidine (1 mg/kg)
Study: 30157913
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (0.5 mg/kg) intravenously for 40 min during dural mater incision.